晚期癌症患者中药物基因组学可干预药物的应用现状
本研究纳入193例晚期癌症患者,评估其门诊用药中具有CPIC治疗推荐(基于胚系变异)的药物比例。结果显示65%患者正在使用至少一种药物基因组学可干预药物,最常见为昂丹司琼(47%)、卡培他滨(10%)和舍曲林(7%)。保守估计7.1%癌症患者可有基因导向的用药调整,每万例基因检测可预防101例不良事件。
要点
- 65%晚期癌症患者使用至少一种药物基因组学可干预药物
- 最常见可干预药物为昂丹司琼、卡培他滨和舍曲林
- 约7.1%患者可基于基因调整用药,每万例检测预防101例不良事件
核心结论
- 药物基因组学相关药物在晚期癌症患者中普遍使用,支持对该高危人群实施前瞻性基因分型以优化治疗。
研究设计与样本
- 基于机构分子肿瘤委员会观察性队列,纳入193例晚期癌症患者,收集人口学、癌症类型和门诊用药数据。
主要发现
- 65%的患者正在服用药物基因组学可干预药物,约占研究人群门诊药物的10%。
- 最常用的可干预药物为昂丹司琼(47%)、卡培他滨(10%)和舍曲林(7%)。
- 保守估计7.1%癌症患者符合基因导向用药调整条件,每万例基因检测可预防101例不良事件。
关键数值与推荐
- 药物基因组学可干预药物定义为有CPIC基于胚系变异的治疗推荐。
临床怎么用
- 临床药师可关注晚期癌症患者中昂丹司琼、卡培他滨和舍曲林等药物的基因检测机会,以调整剂量或预防不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prevalence of pharmacogenetically actionable medications in advanced cancer patients whose therapy may be optimized with genotype data was determined. METHODS: Patients enrolled in our institutional molecular tumor board observational cohort were included in this study. Collected data included demographics, type(s) of cancer, and outpatient medications. Medications were classified as "pharmacogenetically actionable" if there are Clinical Pharmacogenetics Implementation Consortium (CPIC) therapeutic recommendations for that medication based on the presence of germline variations. The prevalence of pharmacogenetically actionable medications in the study population was determined, and the frequency of opportunities for pharmacogenetic prescribing and adverse event (AE) mitigation were estimated. RESULTS: In a cohort of 193 patients with advanced cancer, 65% of patients were taking a pharmacogenetically actionable medication. Approximately 10% of the outpatient medications taken by the study population had a pharmacogenetic association. The most common pharmacogenetically actionable medications being used were ondansetron (47%), capecitabine (10%), and sertraline (7%). Using published genetic variation frequencies and AE risk, we conservatively estimated that 7.1% of cancer patients would be eligible for genetic-based medication adjustment, and 101 AEs would be prevented in 10,000 patients genotyped. CONCLUSION: Medications with pharmacogenetic associations are used commonly in the advanced cancer patient population. This widespread exposure supports the implementation of prospective genotyping in the treatment of these high-risk patients.
引用
- Nichols D, Arnold S, Weiss HL, et al. Pharmacogenomic potential in advanced cancer patients. Am J Health Syst Pharm. 2019. PMID: 31361818. doi:10.1093/ajhp/zxy079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。